December 16, 2020
1 min watch
Save
Clinicians face challenges in diagnosis, treatment of RCC
Healio spoke with Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, about important issues in the diagnosis and treatment of renal cell carcinoma.
Major concerns include detecting RCC earlier, especially during the COVID-19 pandemic, as well as a lack of a proven neoadjuvant strategy for high-risk patients after surgery, she said.
Click here to watch the next video in the series on selecting combination therapies for patients with RCC.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Plimack reports serving as a scientific advisor for Bristol-Myers Squibb, Genentech, MEI, Merck and Seattle Genetics; conducting data safety monitoring for AstraZeneca, Pfizer and Infinity Pharma; receiving honorarium for CME presentations from ASCO GU, Clinical Care Options, Fox Chase Cancer Center, Mt. Sinai Icahn School of Medicine, NCCN, The Ohio State University, OncLive, PER, Research to Practice, Spire Learning and University of Hawaii; and receiving grants for clinical research from Astellas, Bristol-Myers Squibb, Genentech and Merck.
Read more about